Nitrik Oksit`in Etkileri ve Patolojik Rolleri

Transkript

Nitrik Oksit`in Etkileri ve Patolojik Rolleri
Nitrik Oksit’in Etkileri ve Patolojik Rolleri
Dr. Yusuf Türköz1,
Dr. Elif Özerol1
1LWULN RNVLW 12 LON NH] HQGRWHO ND\QDNOÕ JHYúHPH IDNW|U RODUDN WDQÕPODQPÕú YH JQP]GH ELU oRN
PHPHOL KFUH YH GRNXODUÕQÕQ IRQNVL\RQODUÕQÕ G]HQOHGL÷L DQODúÕOPÕúWÕU 12 DUJLQLQLQ QLWULN RNVLW VHQWHWD]
126 HQ]LP DLOHVL WDUDIÕQGDQ RNVLWOHQPHVL\OH \D NRQVWLWXWLI HVDV YH NDOVL\XPD ED÷ÕPOÕ \D GD LQGNOHQHELOLU
YH NDOVL\XPGDQ ED÷ÕPVÕ] RODUDN VHQWH]OHQLU (QGRMHQ RODUDN UHWLOHQ 12 NRQDN VDYXQPDVÕ YH LPPQLWH\L
HWNLOHGL÷L JLEL NDQ GDPDU WRQXVX YH Q|URQDO LOHWL GDKLO ELUoRN IL]\RORMLN ROD\ODUÕQ G]HQOHQPHVLQGH |QHPOL ELU
rol oynar. NO, benzersiz bir biyolojik haberci moleküldür. Sinir sisteminde fizyolojik ve patolojik rolleri
YDUGÕU 6LQLU VLVWHPL PRUIRJHQH]LQGH YH VLQDSVODUÕQ úHNLOOHQPHVLQGH URO R\QDU Q|URWUDQVPLWWHU VDOÕQÕPÕQÕ YH
JHQ HNVSUHV\RQXQX G]HQOH\HELOLU 12 DúÕUÕ UHWLOPHVL KDOLQGH oHúLWOL VLQLU VLVWHPL KDVWDOÕNODUÕQGD |QHPOL
ELU Q|URWRNVLQ RODUDN NDUúÕPÕ]D oÕNPDNWDGÕU $\UÕFD ELU oRN oDOÕúPDGD 12¶LQ LQIODPDWXYDU FHYDSODUÕ
PRGOH HWPHGH NRPSOHNV ELU URO R\QDGÕ÷Õ DQODúÕOPÕúWÕU >7XUJXW g]DO 7ÕS 0HUNH]L 'HUJLVL 461]
Anahtar Kelimeler: Nitrik oksit, nitrik oksit sentetaz, NO, NOS, nörotoksin
Nitric oxide : actions and pathological roles
Nitric oxide (NO), first identified as an endothelium-derived relaxation factor (EDRF), is now recognized
as a regulator of many mammalian cells and tissue functions. It is synthesized via the oxidation of arginine
by a family of nitric oxide synthases (NOS) which are either constitutive and calcium-dependent or inducible
and calcium-independent. The endogenous production of NO plays a vital role in regulating physiological
processes, e.g., blood vessel tone and neurotransmission, as well as in host defense and immunity. NO is a
unique biological messenger molecule. Nitric oxide have physiological and pathophysiological roles in the
nervous system. Nitric oxide may regulate neurotransmitter release, and it may play a key role in nervous
system morphogenesis and synaptic plasticity and regulate gene expression. Under conditions of excessive
formation, nitric oxide is emerging as an important neurotoxin in a variety of disorders of the nervous
system. In addition, in many studies it has been found that nitric oxide plays a complex role in modulating
the inflammatory response. [Journal of Turgut Özal Medical Center 1997;4(4):453-461]
Key Words: Nitric oxide, nitric oxide synthase, NO, NOS, neurotoxin
ELU
\ÕO
DWÕ÷Õ
\ÕOÕQGD
JHYúHPH
HGLOPHVL
GDKD
QLWULN
RNVLGLQ
12
GúQOPHNWH\GL
HQGRWHOLQGHQ
('5)
VÕUDVÕQGD
YH
NDGDU
ROGX÷X
GDPDU
IDNW|U
NHúIHGLOPLú
1
|QFHVLQH
DWPRVIHU
RODUDN
QLWULN
VRQUDNL
HQGRWHO
ELOLQHQ
RNVLW
ND\QDNOÕ
\DSÕQÕQ
VHQWHWD]
\ÕOODUGD
EDVLW
$QFDN
L]ROH
126
('5)
QLQ
12
ROGX÷X
12
WHVSLW
HGLOPLúWLU
UHWHELOGLNOHULQLQ
NDGDU
LQVDQ
YFXGXQGD
PHWDEROL]PDVÕ
IL]\RORMLN
YH
RUWD\D
KDNNÕQGD
SDWRORMLN
oRN
øQVDQ
YH
NRQPDVÕ
KD\YDQODUÕQ
LOH
EXOXQXú
D]
ROD\ODUGDNL
úH\
QHGHQL
ELOLQHQ
URO
GD
\ÕOÕQD
YH
12¶LQ
DQODúÕOPÕú
YH
GH \ÕOÕQ PROHNO VHoLOPLúWLU øQ|Q hQLYHUVLWHVL 7ÕS )DNOWHVL %L\RNLP\D $QDELOLP 'DOÕ 0DODW\D
Journal of Turgut Özal Medical Center 4(4):1997
453
Nitrik oksit’in etkileri ve patolojik rolleri
Y. Türköz ve ark.
12 UHQNVL] ELU JD]GÕU <NVHN NRQVDQWUDV\RQGDNL
NO oksijensiz ortamda oldukça stabil olup suda erime
|]HOOL÷L
RNVLMHQ
J|VWHULU
sürede O2
¶OH
1LWURMHQ
1LWULN
oLIWOHQPHPLú
KFUH\H
DOPDNWDGÕU
oRN
G|QúU
'L÷HU
LoLQ
ELU
VHUEHVW
|QHPOL
DúÕUÕ
YH
YH
KFUHGHQ
NROD\OÕNOD
12
UDGLNDO
]DUDUOÕ
ELU
WDúÕPDPDVÕ
]DPDQGD
QHGHQL\OH
KFUHOHU
$QFDN
\N
NÕVD
]DUDUOÕ
NDUúÕODúPDGDQ
$\QÕ
LVLPOHQGLULOHELOLU
NRQVDQWUDV\RQODUGD
GLRNVLW¶H
ROGXNoD
12
12
EXOXQGXUPDVÕ
EDUL\HUOH
NRQVDQWUDV\RQGD
URO
LoLQ
]HULQGH
VD÷ODPDNWDGÕU
HOHNWURQ
+DYDGDNL
QLWURMHQ
GRNXODU
HOHNWURQ
oLIWOHQPHPLú
NRQVDQWUDV\RQGDNL
VWDELOGLU
RNVLWLQ
KLoELU
JHoPHVLQL
GúN
GDKL
RNVLWOHQHUHN
GLRNVLW
ELOHúLNWLU
RODUDN
LNHQ
YDUOÕ÷ÕQGD
WDúÕGÕ÷Õ
PROHNO
UDGLNDOOHU
LNHQ
12
IL]\RORMLN
NRQWUROV]
KHU
GúN
LúOHYOHUGH
12
VHQWH]L
KFUHOHU LoLQ ]DUDUOÕ ROPDNWDGÕU 12 EX |]HOOLNOHUL LOH
oRN
LGHDO
ELU
IL]\RORMLN
KDEHUFL
PROHNO
|]HOOL÷L
2
nazaran
DIILQLWH\OH
ED÷ODQÕU
NRQVDQWUDV\RQGDNL
KHPRJORELQH
+HPRJORELQ
RNVL
nitrata (NO3
GRODúÕPGDNL
NDW
ELU
IRUPXQGD
RNVLWOH\HUHN
2’e
12
LVH
12¶L
NÕVD
HWNLVL]OHúWLULU
RNVLKHPRJORELQ
12
LoLQ
VUHGH
g]HOOLNOH
NXYYHWOL
ELU
inhibitördür. NO, nitrite de (NO2) okside olabilir
DQFDN
QLWULW
WHNUDU
RNVLWOHQHUHN
NÕVD
VUHGH
QLWUDWD
G|QúP J|VWHULU 12 GL÷HU VHUEHVW UDGLNDOOHU JLEL
oRN
NÕVD
\DUÕODQPD
VUHVLQH
VDKLS
ROXS
RNVLW
DUWWÕ÷Õ
++
&D
GXUXPODUGD
VHQWHWD]
126
YFXGXQ
oRN
ODUMLQLQGHQ 12 VHQWH]L JHUoHNOHúLU ùHNLO $QFDN
VHQWH] VUHVLQLQ oRN NÕVD ROPDVÕ
PLNWDUÕQÕQ
oRN
GúN
ROPDVÕQD
VHQWH]OHQHQ 12
QHGHQ
ROPDNWDGÕU
Çünkü hücre içi iyonize kalsiyum konsantrasyonu
D]DOPD\D EDúODGÕ÷Õ DQ HQ]LP LQDNWLI IRUPD JHoHUHN
12
VHQWH]L
GXUPDNWDGÕU
NDOPXGROLQOH
DNWLYH
ED÷ÕPOÕ126
(Q]LP
ROPDVÕ
YH\D
QHGHQL
NDOVL\XP
LOH
NDOVL\XPD
NRQVWLWXWLI126
RODUDN
VÕQÕIODQGÕUÕOPÕúWÕU VDQL\H
LoLQGH GDKD VWDELO ELU \DSÕ RODQ QLWUDWD RNVLWOHQLU 1LWULN
NRQVDQWUDV\RQXQXQ
NDOPRGXOLQOH ELUOHúHUHN 126 HQ]LPLQL DNWLYH HGHU YH
ND]DQPDNWDGÕU 'úN
ùHNLO 126¶ÕQ DNWLYH HGLOPHVL YH 12 VHQWH]OHQPHVL
GH÷LúLN
øQGNOHQHELOLU QLWULN RNVLW VHQWHWD] L126: Bu
tip NOS, konstitutif
tipin aksine hücre içinde
bulunmaz. Özellikle makrofaj (monosit, nötrofil,
GRNXODUÕQGDQ GDPDU HQGRWHOL EH\LQ PDNURIDM ULQHU
KHSDWRVLW
VLVWHP
GRNXODUÕ
YE
L]ROH
HGLOHUHN
IL]LNRNLP\DVDO
YH
YH
GL÷HUOHUL
VLWRNLQOHUOH
DNWLYDV\RQX
VHQWH]LQH
\RO
ve
NRQVDQWUDV\RQGD
NLQHWLN
|]HOOLNOHUL
NDWDOL]H
HWWL÷L
J|VWHULOPLúWLU
PDNURIDMODU
LQFHOHQPLúWLU
UHDNVL\RQ
UHDNVL\RQ
KFUHOHULQGH
126
ÕQ
LQGNVL\RQX
PLNWDUGD
12
12
EDNWHUL
interferon-γ veya
OLSRSROLVDNNDULWOH
oRN
YH
g]HOOLNOH
yüksek
X\DUÕODQ
UHWHUHN
\DEDQFÕ
D\QÕ
126
LQ
ùHNLO
]DPDQGD
¶GH
l-arjinin-
nitrik oksit yolu olarak ta bilinmektedir.
NOS, incelenen fiziko-kimyasal ve kinetik
|]HOOLNOHULQH J|UH LNL JUXED D\UÕOPDNWDGÕU
1-Konstitutif nitrik oksit sentetaz (cNOS): Bu
øQGNVL\RQ
JQOHUFH
PLNWDUGD
12
12
HGHELOLU
VHQWH]L
VHQWH]L
$QFDN
PDNURIDM
YH
VDDWOHUFH
X]XQ
GL÷HU
KDWWD
VUHOL
DúÕUÕ
GRNXODUGD
GD
harabiyete yol açar. Enzim indüksiyonu l-arjinin
DQDORJODUÕ
YH
JOXNRNRUWLNRLGOHUFH
LQKLEH
edilebilmektedir. Bu indüksiyon, nonspesifik hücre
LPPQLWHVL
LOH
JHOPHNWHGLU
periferik ve santral sinir sistemi gibi dokularda
LQGNOHQHELOLU
ORNDOL]H ROPXúWXU 126 EX GRNXODUGD KHU ]DPDQ
++
PHYFXWWXU DQFDN DNWLI GH÷LOGLU +FUH LoL L\RQL]H &D
VRQUDVÕ
GHYDP
L]RHQ]LP |]HOOLNOH GDPDU HQGRWHOL LGUDU \ROX GRNXODUÕ
454
HQGRWHO
hücrelerde (bakteri, parazit, tümör hücresi) sitostatik
ve/veya sitotoksik etki meydana getirirler (13).
EL\RNLP\DVDO
%X
GDPDU
DoPDNWDGÕU
lipopolisakkaritleri
ùHNLO . L-Arjinin-nitrik oksit yolu
YH
sentez edilmektedir (4). Bu hücrelerin spesifik
LOLúNLOL
(Q]LP
ELU
ELOLQHQ
YH\D
PHNDQL]PD\OD
EX
PH\GDQD
|]HOOLNOHULQGHQ
NDOVL\XPGDQ
GROD\Õ
ED÷ÕPVÕ]126
RODUDN LVLPOHQGLULOPLúWLU 7XUJXW g]DO 7ÕS 0HUNH]L 'HUJLVL Türköz Y, et al.
Nitric oxide : actions and pathological roles
Birçok hormon ve ilaçlar hücre içi etkilerini hücre
\]H\LQGH
LoL
VSHVLILN
VLNOLN
$03
J|VWHULUOHUNHQ
YHYH\D
UHVHSW|UOHUH
12
VOIU
ED÷ODQDUDN
NRQVDQWUDV\RQXQX
KFUH
LoHUHQ
PHPEUDQÕQÕ
SURWHLQOHUH
YH
KFUH
DUWWÕUDUDN
JHoHUHN
ED÷ODQDUDN
GHPLU
HWNLVLQL
çevirmektedir. Bu durumda insan ve hayvanlarda
HQGRWHO
ND\QDNOÕ
ROGX÷X
VDGHFH
LoLQ
YD]RGLODWDV\RQ
KLSHUWDQVL\RQ
VLVWHPLN
GRODúÕPÕQ
UHJODV\RQXQX
D\UÕFD
ORNDO
GRODúÕPÕ
G]
1RQNROLQHUMLN YH QRQDGUHQHUMLN WHUPLQDOOHUGHQ VDOÕQDQ
PHPEUDQÕQGD
EXOXQDQ
JXDQLODW
VLNOD]Õ
GD
UHJOH
aktive eder. Guanilat siklaz ise GTP’den bir ikincil
12
KDEHUFL
düzenlenmektedir (4,9).
F*03
RODQ
VLNOLN
NHQGLQH
*03
X\DQ
F*03
NDV
ROXúXPXQX
JHYúHPHVL
DUWWÕUÕU
VLQDSVWDQ
YD]RGLODWDW|U
JLEL
KFUH
LoL
SURVHVOHUL
UHJOH
HGHU
HWNL\OH
JLEL
RUJDQODUGD
HWPHNWHGLU
NDQ
EDVÕQFÕ
YH
DNÕúÕQÕ
X\DUÕ
%X
JHoLúL
EH\LQ
12
VD÷ODPDNOD
NDOPD]
KFUH
NDUDFL÷HU
LQKLEH
JHOPHNWHGLU
göstermektedir (9). NO özellikle nöronlar ve damar
NDV
NDOS
PHNDQL]PDVÕ
PH\GDQD
YD]RGLODWDV\RQ
PHNDQL]PDVÕ
GDKLOL
ELU
%|\OHFH
NO, guanilat siklaz aktivitesini etkileyerek damar
QLWURYD]RGLODWDV\RQ
göstermektedir.
VLVWHPLQLQ
Çünkü
YDUOÕ÷ÕQÕ
nitrogliserin
ve
Na-
GLODWDV\RQX VLQLUOHUGHQ X\DUÕ JHoLúL JLEL IRQNVL\RQODUÕ
QLWURSUXVVLG JLEL QLWURELOHúLNOHUL X]XQ \ÕOODU NOLQLNOHUGH
JHUoHNOHúWLUPHNWHGLU
(QGRWHO
ND\QDNOÕ
12
KLSHUWDQVL\RQXQ
WHGDYLVLQGH
NXOODQÕOPÕúWÕU
9FXGD
GDPDU G] NDVODUÕQÕQ JHYúHPHVLQL VD÷OD\DUDN NDQ DNÕúÕ
YHULOHQ EX PDGGHOHU VRQXoWD 12
H G|QúHUHN HWNLOHULQL
YH
EDVÕQFÕQÕQ
D\DUODQPDVÕQÕ
VD÷ODPDNWDGÕU
%X
HWNL
J|VWHUPHNWHGLUOHU ùHNLO VLVWHPLN
NDOS
GRODúÕPGD
EH\LQ
PH\GDQD
NDUDFL÷HU
JHOGL÷L
JLEL
ORNDO
JDVWURLQWHVWLQDO
RODUDN
VLVWHPOHUGH
gözlenebilmektedir (4,18).
'DPDU
HQGRWHOLQGHQ
VDOÕQDQ
12
LQ
G] NDV KFUHOHULQGH JXDQLODW VLNOD]ÕQ
HWNLVL
GDPDU
DNWLYDV\RQX
LOH
EDúODU KFUH LoL VLNOLN JXDQR]LQ PRQR IRVIDW F*03
12
PHUNH]L
VLQLU
VLVWHPLQGH
KDIÕ]D
ROXúXPX
NRQVDQWUDV\RQXQXQ DUWÕúÕ YH G] NDVODUÕQ JHYúHPHVL LOH
GHQJH
X\DUÕ
JHoLúL
NRNX
GHVWHNOH\HQ
ELU
DOPD
JLEL
ELUoRN
VRQODQÕU IRQNVL\RQODUÕ
Q|URWUDQVPLWWHU
RODUDN
fonksiyon göstermekte ve etki etmektedir (19).
Periferik sinir sisteminde ise nonadrenerjik ve
nonkolinerjik sinirleri etkileyerek vazodilatasyon,
trombosit
VROXQXP JHQLWRULQHU YH PLGH EDUVDN IRQNVL\RQODUÕQÕQ
sentez ederek trombosit aktivasyonunun kontrolüne
UHJOH HGLOPHVLQH NDWNÕGD EXOXQPDNWDGÕU NDWNÕGD EXOXQPDNWDGÕUODU 'RODúÕP
VLVWHPLQGH
DGH]\RQXQXQ
WURPERVLW
HQJHOOHQPHVL
G]HQOHQPHVL
JLEL
ROD\ODUD
12¶LQ EX IRQNVL\RQODUÕ
KFUH
LoL
VLNOLN
GD
JXDQLODW
*03
DJUHJDV\RQXQXQ
NDOS
YH
NDVÕOPDVÕQÕQ
LúWLUDN
VLNOD]ÕQ
HWPHNWHGLU
DNWLYDV\RQX
NRQVDQWUDV\RQXQXQ
12
SURVWDVLNOLQOH
VLQHUMLVW
agregasyonunu
HQJHOOHPHNWHGLU
ELU
HWNLOHúLPOH
ve
$\UÕFD
adezyonunu
WURPERVLWOHU
GH
12
Kliniklerde, nitrovazodilatörler (nitrogliserin, NaQLWURSUXVVLG
JLEL
LOH
SURVWDVLNOLQ
YH\D
DQDORJODUÕQÕQ
kombine edilmesi çok etkili bir antitrombotik tedavi
VD÷OD\DELOLU
DUWÕúÕ
12¶LQ
oRN
|QHPOL
ELU
GL÷HU
HWNLVL
GH
O|NRVLW
úHNOLQGH FHUH\DQ HWPHNWHGLU Nitrik oksidin fizyolojik ve patolojik rolü
Kardiovasküler ve pulmoner sistemlerde nitrik
oksit:
(QGRWHO
12
ND\QDNOÕ
ROGX÷X
VD\ÕGD
oDOÕúPD
DQDORJODUÕ
1,2
YH
RUDQODUGD
LOH
VRQUDNL
/11$
126
LQKLEH
\ÕOODUGD
HWPHNWHGLU
('5)
\DSÕODQ
g]HOOLNOH
/1$0(
LQKLELW|UOHUL
HQGRWHO
ile
IDNW|UQQ
GR÷UXODQPÕúWÕU
/10$
GL÷HU
GHQHPHOHULQGH
edilmesi
JHYúHPH
KLSRWH]L
/&3$
HQ]LPL
<DSÕODQ
ND\QDNOÕ
vazokonstriksiyon
oRN
ODUMLQLQ
/
GH÷LúLN
LQKLELV\RQ
126
LQ
ve
LQKLEH
sonuçta
KLSHUWDQVL\RQ RUWD\D oÕNPDNWDGÕU Bu inhibitörlerin insan ve hayvanlara verilmesi,
ùHNLO 1LWURELOHúLNOHULQLQ HQGRWHO YH
12
VHQWH]LQL
GXUGXUXODUDN
YH\D
D]DOWDUDN
12¶ÕQ
G]
NDV
KFUHOHULQGH
12
H
G|QúP
JHUHNOL
ROGX÷X
EWQ
IRQNVL\RQODUÕ
Journal of Turgut Özal Medical Center 4(4):1997
WHUVLQH
455
Nitrik oksit’in etkileri ve patolojik rolleri
aktivasyonunu
engelleyerek
Y. Türköz ve ark.
lökositlerin
damar
GXYDUÕ\OD NDUúÕOÕNOÕ HWNLOHúLPL HQJHOOHPHVLGLU D]DOGÕ÷Õ
YH
12¶LQ SDWRORMLN RODUDN VDOÕQÕPÕ
.DQ
EDVÕQFÕQÕQ
X\DUÕODQ
'DPDU
HQGRWHOL
LQGNOHQHELOLU
YH
126
G]
ED]Õ
NDVODUÕQGD
VLWRNLQOHU
EXOXQDQ
YH\D
DUWÕUDQ
HQGRWRNVLQ
LQGNOHQLU
HQGRWHOL
JHOPHNWHGLU
)L]\RORMLN
PH\GDQD
ROXúDQ
YH
JHOLU
ELU
G]
NDVODUÕQGD
øQGNVL\RQ
%X
GLUHQo
ROD\
úDUWODUGD
D\QÕ
VRQXFX
VDGHFH
DQGD
LIDGH
HGLOHELOLU
NDUúÕ
126
ÕQ
indüksiyonu
NOS
inhibitörleri
ve
glukokortikosteroidler ile engellenebilir. Bununla
LOJLOL
RODUDN
KD\YDQODUGD
FHYDEÕQ
YH\D
DVHWLONROLQ
WDUDIÕQGDQ
DUWHULRVNOHUR]OX
KDVWDODUGD
sigara tiryakilerinde ve ailesel yüksek kolesterollü
ER]XOPDNWDGÕU
HQGRWRNVLN
YH
VHSWLN
úRNWD
YDVNOHU
%X
KDVWDODUD
IRQNVL\RQ
ODUMLQLQ
ER]XNOX÷XQX
düzeltebilmektedir (37,38 ).
PH\GDQD
YD]RGLODWDV\RQ
YD]RNRQVWULNW|UOHUH
RODUDN
NDUúÕ
OLSRSROLVDNNDULWOHU
konstitutif NOS (cNOS) aktiftir (4). Bu indüksiyon,
GDPDU
DMDQODUD
VLWRNLQ
YHULOPHVL
WDUDIÕQGDQ
DUWÕúÕ
YD]RGLODWDV\RQ
oRFXNODUGD
VDOÕQÕPÕQÕ
YD]RNRQVWULNW|U
VÕNOÕNOD ]D\ÕIODGÕ÷Õ WHVSLW HGLOPHNWHGLU (QGRWHO ND\QDNOÕ
KDVWDODUGD
12
GD
VHQWH]LQLQ
EX
KDVWDODUGD
KLSHUWDQVL\RQD
/10$
KLSHUWDQVLI
GXUXPGD
KLSHUWDQVL\RQOX
dQN
VHEHS
(NVSHULPHQWDO oDOÕúPDODUGD KD\YDQD
LQKLELW|U
YHULOPHVL
JHUoHN
DNVDPDVÕ
ROPDNWDGÕU 126
JHYúHPH
D]DOPDNWDGÕU
JORPHUOHU
/1$0(
FHYDEÕ
KDVDU
YH
GL÷HUOHUL
DUWÕUPDNWDGÕU
YH
VRG\XP
%X
DWÕOÕPÕQGD
KLSRWDQVL\RQ PH\GDQD JHOLúL |UQHN YHULOHELOLU azalma meydana gelmektedir (41,42). Hipertansiyona
meyilli hayvanlara l-arjinin verilmesi hipertansiyon
Yine kanserli hastalarda sitokin tedavisi de bu yolla
ROXúXPXQX
KLSRWDQVL\RQD QHGHQ ROPDNWDGÕU ùHNLO JHUoHN
12
VHQWH]LQLQ
DúÕUÕ
DUWÕúÕ
YH
EXQD
ED÷OÕ
RODUDN
NXYYHWOH
HQJHOOHPHNWHGLU
KLSHUWDQVL\RQOX
HQI]\RQX
VLVWROLN
GúUPHNWHGLU
YH
YH
VD÷OÕNOÕ
GLDVWROLN
LQVDQODUD
EDVÕQFÕ
dQN
ODUMLQLQ
NÕVD
VUHGH
$QMLRWHQVLQNRQYHUWLQJ
HQ]LP
inhibitörleri ile tedavide bradikinin, endotelden NO
VDOÕQÕPÕQÕ
VLWLPOH
DUWÕUPDNWD
YH
HGHUHN
12
YD]RGLODWDV\RQD
NRQVDQWUDV\RQX
QHGHQ
ROPDNWDGÕU
(QGRWHO ND\QDNOÕ JHYúHPHQLQ GLDEHWOL KD\YDQODUÕQ NDQ
GDPDUODUÕQGD YH NDOSDNFL÷HU WUDQVSODQWDV\RQX \DSÕODQ
LQVDQODUÕQ
YH
L]ROH
DNFL÷HU
DUWHUOHULQGH
YD]RNRQVWULNW|UOHUH
FHYDEÕQ
ROGXNoD
D]DOGÕ÷Õ
]D\ÕIODGÕ÷Õ
WHVSLW
HGLOPLúWLU L-arjinin metil türevleri (L-NMA, L-NAME ve
GL÷HUOHUL
QRUPDO
DWÕOPDNWDGÕU
ùHNLO . NOS ve NO’in indüksiyonunu etkileyen faktörler
Kardiovasküler
NO'in önemi
E|EUHN
ve pulmoner sistemlerde
%X
úDUWODUGD
\DSÕODUÕQ
\HWPH]OL÷L
RODQ
LGUDUOD
SOD]PD
KDVWDODUGD
YFXW
GÕúÕQD
G]H\OHUL
DúÕUÕ
DNXW
GHUHFHGH
yükselmektedir (44). Bu inhibitörlerle NO sentezinin
inhibisyonu, hipertansiyon ve lökositlerde fonksiyon
ER]XNOX÷XQD QHGHQ ROPDNWDGÕU
126¶Õ ODUMLQLQ PHWLO
WUHYOHUL GÕúÕQGD LPLGD]RO WUHYOHUL YH DPLQRJXDQLGLQ
(QGRWHO\DO
ROPDNWDGÕU
ND\QDNOÕ
$UWHU
12
HQGRWHO
dilatasyona neden
YD]R
GRNXVX
YHQ
dokusuna göre daha fazla NO sentez edebilmekte ve
EX
QHGHQOH
JHYúHPHGHQ
özellikle
DUWHUOHUGHNL
GDKD
arteriyel
ID]OD
veya
JHYúHPH
ROPDNWDGÕU
venöz
YHQOHUGHNL
%X
koroner
gibi kimyasal ajanlar da inhibe etmektedir (45).
HQGRWHO
%D]Õ
DNFL÷HU
KDVWDOÕNODUÕQGD
KDVWD\D
LQKDODV\RQOD
NO verilmesi pulmoner hipertansiyonu normale
çevirebilmektedir (46). 13-36 ppm düzeyinde inhale
IDUNOÕOÕN
bypass
HGLOHQ
12
\HWLúNLQOHUGH
UHVSLUDWXYDU
GLVWUHV
VHQGURPXQX |QOHPHNWHGLU $NFL÷HU IRQNVL\RQODUÕ
JUDIWODUÕQÕ
HWNLOH\HQ
|QHPOL
ELU
IDNW|U
ROXS
DUWHU
ER]XOPXú
JUDIWODUÕQÕQ
YHQ
JUDIWODUÕQD
J|UH
GDKD
VÕN
KDVWDODUGD
JQON
12
WHGDYLVL
VROXQXP
DoÕOPDVÕQÕQ
IRQNVL\RQODUÕQÕ
QRUPDOL]H
HWPHNWHGLU
%X
QHGHQLQL ROXúWXUPDNWDGÕU VRQXoODU
Arteriosklerotik kalp arteri ile normal kalp arteri
HQGRWHO
ND\QDNOÕ
DUWHULRVNOHURWLN
456
JHYúHPH
GDPDU
DoÕVÕQGDQ
NDUúÕODúWÕUÕOÕUVD
KDONDODUÕQGD
12
ER]XNOXNODUÕQÕQ
LQKDODV\RQXQXQ
G]HOPHVLQH
DNFL÷HU
IRQNVL\RQ
\DUGÕPFÕ
ROGX÷XQX
RUWD\D NR\PDNWDGÕU
JHYúHPHQLQ
7XUJXW g]DO 7ÕS 0HUNH]L 'HUJLVL Türköz Y, et al.
Nitric oxide : actions and pathological roles
øQKDOH HGLOHQ 12
LQ |]HOOLNOH DNFL÷HU DOYHROOHULQGH
NDSLOOHU
GDPDUODUÕ
YHQWLODV\RQSHUI]\RQ
HGLOPLúWLU
DNFL÷HUOHUGH
JHQLúOHWWL÷L
RUDQÕQÕ
6ROXQXPOD
ORNDO
DOÕQDQ
HWNL
YH
G]HOWWL÷L
WHVSLW
12
VDGHFH
J|VWHUPHNWH
VLVWHPLN
GRODúÕPGD KHUKDQJL ELU HWNL PH\GDQD JHWLUPHPHNWHGLU
1RUPDO
SSE
úDUWODUGD
G]H\LQGH
LQVDQODUÕQ
12¶L
VROXQXP
YFXW
KDYDVÕ
GÕúÕQD
LOH
DWWÕ÷Õ
WHVSLW
HGLOPLúWLU 6LUR]XQ
KLSHUGLQDPLN
ID]ÕQGD
NDQGD
\NVHN
NRQVDQWUDV\RQGD HQGRWRNVLQ YD]RNRQVWULNW|UOHUH NDUúÕ
FHYDEÕQ
D]DOPDVÕ
ROPDNWDGÕU
YH
DúÕUÕ
dQN
LQGNOH\HUHN
DúÕUÕ
YD]RGLODWDV\RQD
PHYFXW
12
QHGHQ
HQGRWRNVLQ
VHQWH]LQH
\RO
DoDU
126¶Õ
6LUR]GD
YH
özellikle hepato-renal sendromda NO’in oksidasyon
UQOHUL
RODQ
QLWUDW
J|VWHUPHNWHGLU
YH
QLWULWLQ
%X
VHUXP
DUWÕú
G]H\OHUL
GLUHNW
DUWÕú
HQGRWRNVLQ
NRQVDQWUDV\RQXQD ED÷OÕ RODUDN GH÷LúPHNWHGLU NO’in sinir sistemindeki rolü:
A. Santral sinir sistemi
Fizyolojik rolü:
ùHNLO . Beyin dokusunda arjinin-NO yolu
Spesifik glutamat reseptörünü etkileyen N-metil D-aspartatla (NMDA) stimüle edilen beyin hücreleri
('5)
EHQ]HUL
\DSÕODUGDQ
\DSÕODU
ELUL
oDOÕúPDODUGD
VHQWH]
GH
EH\LQ
12
HGHUOHU
GLU
ùHNLO
GRNXVXQGD
DNWLI
%X
<DSÕODQ
oDOÕúDQ
Patolojik rolü:
Eksite edici amino asitlerin (aspartat, glutamat)
DUMLQLQ
DúÕUÕ
12
\ROXQXQ
YDUOÕ÷Õ
LVSDWODQPÕúWÕU
12
reseptörleri etkilemekte ve hücre içindeki cGMP
NRQVDQWUDV\RQXQX
J|VWHUPHNWHGLU
VLQLUVHO
LOHWL
DUWWÕUDUDN
*OXWDPDW
LúOHPLQGH
IL]\RORMLN
WDUDIÕQGDQ
12
LQ
ELU
VDOÕQÕPÕ
NRQYOVL\RQ
YH
Q|URWRNVLVLWH\H
QHGHQ
EX
ROPDNWDGÕU
X\DUÕOPDVÕ
YH
%X
DPLQR
DVLWOHUOH
VRQUDVÕQGD
126¶ÕQ
UHVHSW|UOHULQ
DNWLYDV\RQX
HWNL
VHUHEUDO
LVNHPL
VHQWH]L
YH
YH
HSLOHSVL
JLEL
GXUXPODUGD
DúÕUÕ
12
LQGNOHQHQ
Q|UDO
GHIHNWOHUH
QHGHQ
ROGX÷X
LOHUL
EXOJXODU
KDOD
Q|URWUDQVPLWWHU
VUOPúWU
%X
KLSRWH]L
GHVWHNOH\HQ
RODUDN URO R\QDGÕ÷Õ WDP RODUDN LVSDW HGLOPLúWLU WDUWÕúPDOÕGÕU
126
LQVDQ
WDUDIÕQGD
oRN
YH
GH÷LúHQ
VD\ÕGD
KD\YDQODUÕQ
RUDQODUGD
oDOÕúPD
12¶LQ
EH\LQ
GRNXVXQXQ
EXOXQPDNWDGÕU
KDIÕ]D
KHU
<DSÕODQ
ROXúXPXQGD
NÕVPHQ
GH ROVD URO DOGÕ÷ÕQÕ RUWD\D NR\PXúWXU øQ YLWUR VSHVLILN
reseptör
stimülasyonundan
ND\QDNWDQ
YH\D
oRN
12
VDOÕQPDNWD
VD\ÕGD
Q|URQX
sonra
YH
postsinaptik
SUHVLQDSWLN
RODUDN
HWNLOHPHNWHGLU
%X
ELU
hücreler,
VDOÕQÕPÕQÕ
GDKD
ID]OD
DUWÕUPDNWD
%H\LQGH
PRQRVLW
indüklenebilen
HGHELOPHNWHGLU
3DUNLQVRQ
%X
tip
KFUHOHU
$O]KHPHLU
WU
NOS
$,'6¶GH
KDVWDOÕ÷Õ
PLNURJOLDO
sentez
KDIÕ]D
0DOWLSO
ND\EÕ
VNOHUR]¶XQ
SDWRJHQH]LQGH GH URO R\QDPDNWDGÕU
$úÕUÕ
UHWLOHQ
12
LQ
QHGHQ
ROGX÷X
EH\LQ
KDVDUÕQD
indüklenebilir veya konstitüv NOS ya da her ikisinin
HWNL
VHEHS
JOXWDPDW
VRQXoWD
ROXS
ROPD\DFD÷Õ
WDP
RODUDN
DQODúÕODPDPÕúWÕU
LVH
$QFDN NRQX LOH LOJLOL DUDúWÕUPDODU \R÷XQ RODUDN GHYDP
VLQDSWLN JHoLú
+DIÕ]D
ROXúXPX
IRQNVL\RQXQXQ
ROGX÷XQX
NR\PXúWXU
J|UPH
DUWÕúOD VRQXoODQPDNWDGÕU
LOH
LOJLOL
ER]XOGX÷X
YH
12
$\UÕFD
LúOHYLQGH
GH
GXUXPODUGD
G]H\LQLQ
12
NRNX
IL]\RORMLN
etmektedir.
oDOÕúPDODU
126
ÕQ
D]DOGÕ÷ÕQÕ
DOPD
D÷UÕ
RODUDN
|÷UHQPH
URO
B. Periferik sinir sisteminde NO
LQKLEH
RUWD\D
GX\XVX
YH
DOPDNWDGÕU
NO, merkezi ve periferik sinir sisteminde bir
nörotransmitter gibi rol oynayarak sinirlerden impuls
JHoLúLQL HWNLOHPHNWHGLU (56).
Journal of Turgut Özal Medical Center 4(4):1997
457
Nitrik oksit’in etkileri ve patolojik rolleri
12
GLODWH
KD\YDQODUGD
HGHUHN
$\UÕFD
\HQL
JDVWUR
VILQNWHUOHULQGH
IL]\RORMLN
NRUSXV
LoL
JHYúHPH\H
\RO
NOS
DoDUDN
UHJOH
øQVDQODUGD
NRUSXV
GRNXVXQGD
12
NRQPXúWXU
%XUDGDQ
HWNL ROXúWXUGX÷X ELOGLULOPLúWLU EX
RUJDQODUÕQ
HGLOPHVLQH
NDWNÕGD
O$UMLQLQ12
\ROX
SHQLV
(OHNWULNVHO
JHYúHPHVL
engellenebilmektedir.
oDOÕúPDODUGD
VHQWH]OH\HQ
GD
viruslarda viral replikasyonu inhibe ederek antiviral
|]HOOLNOH
NDYHUQR]XPXQ
inhibitörlerince
øPPQRKLVWRNLP\DVDO
PLGH\L
JHYúHPHVL\OH
VD÷ODPDNWDGÕU
ROXúWXUXODQ
NDUúÕ
VD÷ODPDNWDGÕU
VLVWHPLQ
NDYHUQR]XPXQ
HUHNVL\RQXQX
EDVÕQFD
X\XPXQX
LQWHVWLQDO
IRQNVL\RQODUÕQÕQ
EXOXQPDNWDGÕU
RODUDN
PLGH
GXUXPD
Y. Türköz ve ark.
LQVDQ
VLQLUOHULQ
DQODúÕODFD÷Õ
SHQLVL
YDUOÕ÷Õ
]HUH
RUWD\D
12
SHQLV
ereksiyonunun önemli bir modülatörüdür (61).
Nonadrenerjik ve nonkolinerjik vazodilatasyonlar
WUDNHDQÕQ
12
JHYúHPHVL
VHQWH]LQLQ
JLEL
LQKLEH
12
LOH
HGLOGL÷L
LOLúNLOL
ROD\ODUGÕU
GXUXPODUGD
LGUDU
NHVHVLQLQ NDSDVLWHVLQLQ D]DOGÕ÷Õ WHVSLW HGLOPLúWLU 12¶L
nörotransmitter olarak kullanan sinir sistemleri ;
adrenerjik, kolinerjik ve peptiderjik sinirler kadar
ùHNLO 0DNURIDM
ND\QDNOÕ
KFUHOHULQGH
12
EDNWHUL
oHúLWOL
SDUD]LW
HQ]LPOHULQ
YH
WP|U
IRQNVL\RQXQX
HWNLOH\HUHN VLWRWRNVLN HWNL \DSPDNWDGÕU
|QHPOL
IL]\RORMLN
NO’i
nörotransmitter
VLVWHPOHULQLQ
KDVDUODUD
LúOHYOHU
IRQNVL\RQ
\RO
J|VWHUPHNWHGLU
olarak
kullanan
ER]XNOXNODUÕ
DoPDNWDGÕU
LOJLOL
sinir
GRNXODUGD
gUQH÷LQ
NRUSXV
Makrofajlardan özellikle monositlerde L-ArjininNO yolu; tümör hücreleri, intra- ve ekstrasellüler
NDYHUQR]XPX X\DUDQ VLQLUOHUGHNL IRQNVL\RQ ER]XNOX÷X
PLNURRUJDQL]PDODUD
NDUúÕ
oRN
|QHPOL
ELU
GHIDQV
LNWLGDUVÕ]OÕ÷D QHGHQ ROPDNWDGÕU
PHNDQL]PDVÕGÕU
Sitotoksik ve sitostatik ajan olarak NO:
øQWHUIHURQ
YH\D
EDNWHUL
Nitrik oksidin immünitedeki rolü:
OLSRSROLVDNNDULWOHUL
<ÕOODU
WDUDIÕQGDQ
DNWLYH
HGLOHQ
PDNURIDMODU
E\N
|QFH
QRQVSHVLILN
12
VHQWH]
durumlarda
HGHUOHU
$NWLYDV\RQXQ
makrofajlarda
NOS
DUDúWÕUÕFÕODU
ED]Õ
EDNWHUL
UQOHUL\OH
PLNWDUGD
ELU
PHNDQL]PD
LOH
NDQVHUH
NDUúÕ
GLUHQFLQ
ROPDGÕ÷Õ
bulunmaz.
DUWWÕUÕODELOGL÷LQL
ELOJLOHULPL]H
J|VWHUPLúOHUGLU
J|UH
EX
GLUHQo
%XJQN
DUWÕúÕ
PDNURIDM
øQGNVL\RQGDQ VRQUD HQ]LP VHQWH]L YH GROD\ÕVÕ\OD 12
sentezi meydana gelmektedir. L-Arjinin-NO yolunun
indüklenmesi, saatlerce hatta günlerce devam eden
DNWLYDV\RQX
QRQVSHVLILN
YH
12
ELU
LPPQ
UHDNVL\RQODU
12
VHQWH]LQH
VHQWH]L
QHGHQ
KFUHOHU
JHWLUPHNWHGLU
ROPDNWDGÕU
LoLQ
ROGXNoD
0DNURIDM
$QFDN
DúÕUÕ
]DUDUOÕ
HWNLOHU
PH\GDQD
ND\QDNOÕ
12
12
VHQWH]L
LOH
ROD\GÕU
PDNURIDM
GR÷UXGDQ
ED÷ODQWÕOÕ
1RQVSHVLILN
DNWLYDV\RQX
LPPQ
126¶ÕQ
indüklenmesi, uzun süreli ve çok miktarda NO
sentezinden ibarettir. Bu nonspesifik immünite sadece
EDNWHUL
parazit ve tümör hücreleri üzerinde sitotoksik etki
5(6¶OH
VÕQÕUOÕ
ROPD\ÕS
KHSDWRVLWOHU
YH
DNFL÷HU
KFUHOHULQGH GH WHVSLW HGLOPLúWLU
\DSPDNWDGÕU ùHNLO NO bakteri, parazit gibi birçok patojenin ve tümör
hücrelerinin ATP üreten oksidatif fosforilasyonun
12¶H
YH
ED÷ÕPOÕ
DNFL÷HULQ
QRQVSHVLILN
URO
EX
LNL
LPPQLWHGH
RUJDQÕQ
NDUDFL÷HU
VLUNODV\RQXQ
LPPQRORMLN ILOWUHOHUL JLEL IRQNVL\RQ J|UHFH÷L VWUDWHMLN
XELNLQRQ UHGNWD]
Õ JOLNROL]LQ JOLVHUDOGHKLGIRVIDW
ELU NRQXPGD \HU DOPDVÕQGDQ ND\QDNODQPDNWDGÕU
GHKLGURMHQD]
Õ
LoHUHQ
ED]Õ
7&$
VLNOXVXQXQ
HQ]LPOHULQL
LQKLEH
&LVDNRQLWD]
Õ
HWPHNWH
YH
)H
VRQXoWD
bakteri, parazit, tümör hücrelerini öldürmektedir (7072). NO, hedef hücrelerde (bakteri, parazit, tümör
KFUHVL
'1$
ULERQNOHRWLG
'1$¶VÕQÕQ
HWNL
458
VHQWH]LQLQ
UHGNWD]Õ
GHDPLQDV\RQX
PH\GDQD
JHWLULU
KÕ]
NÕVÕWOD\ÕFÕ
EORNH
LOH
EX
HGHU
HQ]LPL
YH
KFUHOHUGH
$\UÕFD
RODQ
KFUH
VWRVWDWLN
12
LQ
ED]Õ
0DNURIDM
ND\QDNOÕ
12
VHQWH]LQLQ
X]XQ
VUHOL
YH
oRN PLNWDUGD UHWLOPHVL DúÕUÕ ELULNHQ 12 PDNURIDM YH
GL÷HU
KFUHOHUGH
0DNURIDMODUÕQ
glikokortikoid
LQGNOHQHELOLU
KDVDU
DNWLYH
ve
PH\GDQD
ROGX÷X
l-arjinin
126¶ÕQ
Õ126
JHWLUHFHNWLU
GXUXPODUGD
türevlerinin
LQKLELV\RQX
|]HOOLNOH
etkisi,
YH
12
VHQWH]LQLQ D]DOPDVÕ \|QQGH RODFDNWÕU %X LQKLELV\RQD
7XUJXW g]DO 7ÕS 0HUNH]L 'HUJLVL Türköz Y, et al.
LODYHWHQ
ED]Õ
PHNDQL]PDODUÕQÕQ
Nitric oxide : actions and pathological roles
WUDQVNULSVL\RQDO
YDUOÕ÷ÕQGDQ
$QFDN EX PHNDQL]PDODU
GD
LQKLELV\RQ
EDKVHGLOPHNWHGLU
WDP RODUDN DoÕNODQDPDPÕúWÕU
KAYNAKLAR
18. Snyder SH. Nitric oxide: First in a new class of
neurotransmitters. Science 1992;257: 494-6.
19. Dawson TM, Dawson VL, Snyder SH. A novel neuronal
messenger molecule in brain: the free radical, nitric oxide. Ann
Neurol 1992;32:297-311.
20. Tottrup A, Glavihd EB, Svane D. Involvement of the Larginine-nitric oxide pathway in internal analspinchter
relaxation. Gastroentrology 1992;102:409-15.
1.
Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G.
Endothelium-derivied relaxing factor produceed and released
from artery and vein is nitric oxide. Proc Natl Acad Sci
USA1987; 84: 9265-9.
2.
Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial
cells synthesize nitric oxide from L-arginine. Nature 1988;
333: 664-6.
22. Calver A, Collier J, Moncada S, Vallance P. Effect of local
intra-arterial NG-monomethyl-L-arginine in patients with
hipertension: the nitric oxide dilator mechanism appears
abnormal. J Hypertens 1992;10:1025-31.
3.
Nussler AK, Billiar TR. Inflammation, immunoregulation and
inducible nitric oxide synthase. J Leukoc Biol (USA)
1993;54(2):171-8.
23. Sogni P, Moreau R, Ohsuga M, Cailmail SiOberti F, Hadengu
A,et al. Evidence for normal nitric oxide-mediated vasodilator
tone in consciosis. Hepatology 1992;16:980-3.
4.
Lowenstein CJ, Dinerman JL, Snyder SH. Nitric oxide: A
physiologic messenger. Ann Intern Med 1994; 120: 227-37.
5.
Moncada S, Palmer RMJ, Higgs A. Nitric oxide: Physology,
Pathophysology, and Pharmacology. Pharmaco Reviews 1991;
43('9: 109-37.
24. McCall TB, Feelisch M, Palmer RMJ, Moncada P.
Identification of N- iminoethyl-L- ornithine as an irreversible
inhibitor of nitric oxide synthase in phagocytic cells. B J
Pharmocol 1991; 102: 234-8.
6.
Star RA. Nitric oxide. Am J Med Sci (USA). 1993;306(5):34858.
7.
Tayeh MA, Marletta MA. Macrophage oxidation of L-arginine
to nitric oxide, nitrite and nitrate: Tetrahydrobiopterin is
required as a cofactor. J Biol Chem. 1989; 264:19654-8.
8.
Moncado S. The L-arginine: Nitric oxide pathway. Acta
Physiol Scand 1992; 145(3): 201-27.
9.
Ignarro LJ. Nitric oxide. A novel signal transduction
mechanism for transcellular communication. Hypertension
(USA) 1990;16(5):477-83.
10. Andersson KE, Persson K. Nitric oxide synthase and nitric
oxide-mediated effects in lower urinary Tract smooth muscle.
World J Urol (Germany) 1994;12(5):274-80.
11. Knowles RG, Moncada S. Nitric oxide senthases in mammals.
Bichem J 1994; 298: 249-58.
12. Marletta MA. Approaches toward selective inhibition of nitrik
oxide synthase. J Med Chem 1994; 37: 1899-907.
13. Cendan JC, Topping DL, Pruitt J, Snowdy J, Copeland EM,
Lind DS. Inflammatory mediators stimulate arginine transport
and arginine-derived nitric oxide production in a murine breast
cancer line. J Surg Res.USA 1996; 60(2): 248-88.
14. Dawson VL. Nitric oxide: role neurotoxicity. Clin Exp
Pharmacol Physiol (Australia) 1995;22(4):305-8.
15. Bachmann S, Mundel P. Nitric oxide in the kidney: Synthesis,
localization and fonction. Am J Kid Diseas 1994; 24(1): 11229.
16. Hevel JM, White KA, Marletta MA,: Pürification of the
inducible murine macrophage nitric oxide synthase.
Identification as aflavoprotein. J Biol Chem 1991; 266: 2278991.
17. Geller DA, Lowenstein CS, Shapiro RA, Nussler AK, Disilvio
N, Wang S, et al. Molecular cloning and expression of
inducible nitric oxide synthase from human hepatocytes. Proc
Natl Acad Sci USA 1993; 90: 3491- 5.
Journal of Turgut Özal Medical Center 4(4):1997
21. Loscalzo J, Welch G. Nitric oxide and its role in the
cardiovasculer system. Prog Cardiovasc Dis (U S A).
1995;38(2):87-104.
25. Bassenge E. Coronary vasomotor responses: role of
endothelium and nitrovasodilators. Cardiovasc Drugs Ther (U
S A). 1994;8(4):601-10.
26. Varela AF, Runge A, Ignarro LJ, Chaudhuri G. Nitric oxide
DQG SURVWDF\FOLQ LQKLELW IHWDO SODWHOHW DJJUHJDWÕRQ D UHVSRQVH
similar to that observed in adults. Am J Obstet Gynecol
1992;167:1599-604.
27. De Graaf JC, Banga JD, Moncada S, Palmer RM, de Groot PG,
Sixma JJ. Nitric oxide functions as an inhibitor of platelet
adhesion under flow conditions. Circulation 1992;85:2284-90.
28. Radomski MW, Palmer RMS, Moncada S. Endogenous nitric
oxide inhibits human platelet adhesion to vascular
endothelium. Lancet 1987; 2: 1057-8.
29. Radomski MW, Palmer RM, Moncada S. Characterization of
the L-arginine:nitric oxide pathway in human platelets. Br J
Pharmacol 1990;101:325-8.
30. Kubes P, Suzuki M, Granger DM. Nitric oxide: An
endogenous modulator of leucocyte adhesion. Proc Natl Acad
Sci USA 1991; 88: 4651- 5.
31. Wolfe TA, Dasta JF. Use of nitric oxide synthase inhibitors as
a novel treatment for septic shock. Ann Pharmacother (USA)
1995;29(1):36-46.
32. Hibbs JB Jr, Westenfelder C, Taintor R, Vavrin Z, Kablitz C,
Baranowski RL, et al. Evidence for cytokine-inducible nitric
oxide synthesis from L-arginine in patients receiving
interleukin-2 therapy. J Clin Invest 1992;89:867-77.
33. Hotchkiss RS, Karl IE, Parker JL, Adams HR. Inhibition of
NO synthesis in septic shock. Lancet 1992;339:434-5.
34. Luscher TF, Diederich D, Siebenmann R, et al. Difference
between endothelium- dependent relaxation in arterial and in
venous coronary bypass grafts. N Eng J Med 1988; 319: 462-7.
35. Cox DA, Vita JA, Treasure CB, et al. Atherosclerosis impairs
flow mediated dilatoin of coronary arteries in human.
Circulation 1989; 80: 458-65.
459
Nitrik oksit’in etkileri ve patolojik rolleri
Y. Türköz ve ark.
36. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive
detection of endothelial dysfuntion in child ren and adulys at
risk of Atherosclerosis. Lancet 1992; 340:1111-5.
37. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of
HQGRWKHOLDO
G\VIXQWLRQ
LQ
FRURQDU\
PLFURFLUFXODWÕRQ
RI
52. Lynch DR, Dawson TM. Secondary mechanism in neuronal
trauma . Curr Opin Neurol (USA) 1994;7(6):510-6.
53. Faraci FM, Breese KR. Nitric oxide mediates vasodilatation in
response to activation of N-methyl-D-aspartate receptors in
brain. Circ Res 1993;72:476-80.
hypercholesterolaemic patients by L- arginine. Lancet 1991;
338: 1546-50.
54. Paakkari I, Lindsberg P. Nitric oxide in the central nervous
system. Ann Med (England) 1995;27(3):369-77.
38. Creager HA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ,
Cooke JP. L-arginine improves endothelium- dependent
vasodilation in hypercholesterolaemic humans. J Clin Invest
1992; 90: 1248- 53.
55. Garthwaite J, Boulton CL. Nitric oxide signaling in the central
nervous system. Annu Rev Physiol (USA) 1995;57:683-706.
39. Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal
HQGRWKHOLXP GHSHQGHQW YDVFXODU UHOD[DWÕRQ LQ SDWLHQWV
ZLWK
essential hypertension . N Eng J Med 1990;323: 22-7.
40. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of
endothelium derived nitric oxide in the abnormal endothelium
dependent vascular relaxation of patients with essential
hypertension. Circulation 1993;87:1468-74.
41. Balis C, Mitruka B, Deng A. Chronic blockade of nitrik oxide
synthesis in the rat produces systemic hypertansion and
glomerular damage. J Clin Invest 1992; 90: 278-81.
42. Yukimura T, Yamashita Y, Miura K, Okumura M, Yamanaka
S, Yamamota K. Renal effects of the nitric oxide synthase
inhibitor; L-NG- niyroarginine, in dogs.Am J Hypertens 1992;
5: 484-7.
43.
(ODEEDG\ $$ *DJQRQ & +DVVRXQD 00 %HJÕQ /5 (OKLODNL
MM. Diabetes mellitus increase nitric oxide synthase in
penises but not in major pelvic ganglia of rats. B J Urol 1995;
76: 196-202.
44. Vallence P, Leone A, Calver A, Colier J, Moncada S.
$FFXPXODWÕRQ
RI
DQ
HQGRJHQRXV
LQKLELWRU
RI
QLWULF
R[LGH
56. Olesen J, Thomsen LL, Iversen H. Nitric oxide is a key
molecule in migraine and other vascular headaches. Trends
Pharmacol Sci (England) 1994;15(5):149-53.
57. Rand MJ, Li CG. Nitric oxide as a neurotransmitter in
peripheral nerves: nature of transmitter and mechanism of
transmission.Annu Rev Physiol (USA) 1995;57:659-82.
58. Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH.
Nitric oxide : a physiologic mediator of penile erection.
Science 1992;257:401-3.
59. Bush PA, Aronson WJ, Buga GM, Rajfer J, Ignarro LJ. Nitric
oxide is a potent relaxant of human and rabbit corpus
cavernosum. J Urol 1992;147:1650-5.
60. Trigo-Rocha F, Aronson WJ, Hohenfellner M, Ignarro LJ,
Rajfer J, Lue TF. Nitric oxide and cGMP: mediators of pelvic
nerve-stimulated erection in dogs. Am J Physiol
1993;264:H419-22.
61. Burnett AL, Tillman SL, Chang TS; Epstein JL, Lowenstein
CJ, Bredt DS, et al. :Immunohistochemical localization of
nitric oxide synthase in the autonomic innervation of the
human penis. J Urol 1993; 150:73-8.
62. Iselin CE, Alm P, Schaad NC, Larsson B, Grabber P,
$QGHUVVRQ .( 1LWULF R[LGH LQKLELWV FRQWUDFWLRQ RI ÕVRODWHG SLJ
synthesis in chronic renal failure. Lancet 1992; 339: 572-5.
45. Corbett JA, McDaniel ML. Does nitric oxide mediate
DXWRLPPXQH
GHVWUXFWÕRQ
RI
EHWDFHOOV"
3RVVLEOH
WKHUDSHXWLF
interventions in IDDM. Diabetes (USA) 1992;41(8):899-903.
46. Roberts JD, Polaner DM, Lang P, Zapol WM. Inhaled nitric
oxide in persistent pulmonary hypertension of the newborn.
Lancet 1992;340:818-9.
47. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM.
Inhaled nitric oxide for the adult respiratory distress syndrome.
N Engl J Med 1993;328:399-405.
48. Pepka-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D,
Wallwork J. Inhaled nitric oxide as a cause of selective
SXOPRQDU\ YDVRGLODWDWÕRQ LQ SXOPRQDU\ K\SHUWHQVÕRQ /DQFHW
1991; 338: 1173-4.
49. Gustafsson LE, Leone AM, Persson MG; Wiklund NP,
Moncada S. Endogenous nitric oxide is present in the exhaled
air of rabbits, guinea pigs and humans. Biochem Biophys Res
Commun 1991; 181: 852-7.
50. Pizcueta P, Pique JM, Fernandez M, Bosch J,Whittle BJ,et al.
Modulation of the hyperdynamic circulation of cirrhotic rats
by nitric oxide inhibition. Gastroenterology 1992;103:1909-15.
51. Nussler AK, Di Silvio M, Billiar TR, Hoffman RA, Geller DA,
Selby R, et al. Stimulation of the nitric oxide synthase pathway
in human hepatocytes by cytokines and endotoxin. J Exp Med
1992;176:261-4.
460
ureteral smooth muscle. J Urol 1996; 155: 763-7.
63.
+D\DVKLGD + 2NDPXUD 7 7RPR\RVKÕ 7 7RGD 1 1RXURJHQLF
nitric oxide mediates relaxation of canine corpus cavernosum.
J Urol 1996; 155: 1122-7.
64. Toda N, Kitamura Y, Okamura T. Role of nitroxidergic nerve
in dog retinal arterioles invivo and arteries invitro. Am J
Physiol 1994; 266: H1985-89.
65. Burnett AL, Takeda M, Maguire MP, Lepor H, Chamness SL,
Chang TSK, Ricker DD. Characterization and localization of
nitric oxide synthase in the human protate. Urology 1995; 45:
435-40.
66. Munoz-Fernandez MA, Fernandez MA, Fresno M. Synergism
between tumor necrosis factor-alpha and interferon-gamma on
macrofage activation for the killing of intracellular
Trypanosoma cruzi through a nitric oxide-dependent
mechanism.Eur J Immunol 1992;22:301-7.
67. Liew FY, Li Y, Millott S. Tumour necrosis factor (TNF-alpha)
in leishmaniasis. II. TNF-alpha-induced macrophage
leishmanicidal activity is.mediated by nitric oxide from Larginine. Immunology 1990;71:556-9.
68. Green SJ, Meltzer MS, Hibbs JB Jr, Nacy CA. Activated
macrophages destroy intracellular Leishmania major
amastigotes by an L-arginine-dependent killing mechanism. J
Immunol 1990;144:278-83.
7XUJXW g]DO 7ÕS 0HUNH]L 'HUJLVL Türköz Y, et al.
Nitric oxide : actions and pathological roles
69. Lin JY, Chadee K. Macrophage cytotoxicity against
Entamoeba histolytica trophozoites is mediated by nitric oxide
from L-arginine. J Immunol 1992;148:3999-4005.
74. Kwon NS, Stuehr DJ, Nathan CF. Inhibition of tumor cell
ribonucleotide reductase by macrophage derived nitric oxide. J
Exp Med 1991;174:761-8.
70. Zhang J, Snyder SH. Nitric oxide stimulates auto-ADPribosylation of glyceraldehyde-3-phosphate dehidrogenase.
Proc Natl Acad Sci USA 1992;89:9382-5.
75. Croen KD. Evidence for antiviral effect of nitric oxide.
Inhibition of herpes simplex virus type 1 replication. J Clin
Invest 1993;91:2446-52.
71. Dimmeler S, Brune B. Characterization of a nitric-oxidecatalaysed ADP-ribosylation of glyseraldehyde-3-phosphate
dehidrogenase. Eur J Biochem 1992;210:305-10.
76. Karupia G, Xie Q, Buller RML, Nathan C, Duarte C,
MacMicking JD. Inhibition of viral replication by interferongamma induced nitric oxide synthase. Science 1993;261:14458.
72. Taylor-Robinson AW, Severn A, Phillips RS. Kinetics of nitric
oxide production during infection and reinfection of mice with
Plasmodium chabaudi. Parasite-Immunology 1996;18-8:42530.
73. Lepoivre M, Feischi F, Coves J, Thelander L, Fontecave M.
Inactivation of ribonucleotide reductase by nitric oxide.
Biochem Biophys Res Commun 1991;179:442-8.
Journal of Turgut Özal Medical Center 4(4):1997
<D]ÕúPD DGUHVL
: Yard.Doç.Dr. Yusuf TÜRKÖZ
øQ|Q hQLYHUVLWHVL 7ÕS )DNOWHVL
44069
Biyokimya ABD
MALATYA
461

Benzer belgeler

RAYNAUD FENOMENİ

RAYNAUD FENOMENİ LoLQ YFXGXQ VR÷XWXOPDVÕ HVQDVÕQGD 5) RODQ NLúLOHUOH VD÷OÕNOÕ ELUH\OHU NDUúÕODúWÕUÕOGÕ÷Õ ]DPDQ

Detaylı